These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 1631803)

  • 1. von Willebrand factor characterization of a severe dry-heat treated factor VIII concentrate, AHF (high purity).
    Oates A; Polmear E; Herrington R; Farrugia A; Sykes S; Raines G; Aumann H; Street A
    Thromb Res; 1992 Feb; 65(3):389-99. PubMed ID: 1631803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial.
    Mannucci PM; Tenconi PM; Castaman G; Rodeghiero F
    Blood; 1992 Jun; 79(12):3130-7. PubMed ID: 1596562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heat-treated factor VIII/von Willebrand factor concentrate in platelet-type von Willebrand's disease.
    Takahashi H; Tatewaki W; Nagayama R; Hanano M; Tamura M; Yamaguchi T; Takizawa S; Wada K; Shibata A
    Haemostasis; 1987; 17(6):353-60. PubMed ID: 3123334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity.
    Goudemand J; Mazurier C; Marey A; Caron C; Coupez B; Mizon P; Goudemand M
    Br J Haematol; 1992 Feb; 80(2):214-21. PubMed ID: 1550779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo evaluation of a factor VIII concentrate heat-treated to inactivate HTLV-III/LAV viruses. Favourable effects of heating on the von Willebrand factor.
    Mazurier C; de Romeuf C; Parquet-Gernez A; Jorieux S; Goudemand M
    Vox Sang; 1987; 52(4):265-71. PubMed ID: 3114955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of von Willebrand factor in factor VIII concentrates.
    Fricke WA; Yu MY
    Am J Hematol; 1989 May; 31(1):41-5. PubMed ID: 2495715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneous abnormalities in the multimeric structure, antigenic properties, and plasma-platelet content of factor VIII/von Willebrand factor in subtypes of classic (type I) and variant (type IIA) von Willebrand's disease.
    Weiss HJ; Pietu G; Rabinowitz R; Girma JP; Rogers J; Meyer D
    J Lab Clin Med; 1983 Mar; 101(3):411-25. PubMed ID: 6186757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate).
    Stadler M; Gruber G; Kannicht C; Biesert L; Radomski KU; Suhartono H; Pock K; Neisser-Svae A; Weinberger J; Römisch J; Svae TE
    Biologicals; 2006 Dec; 34(4):281-8. PubMed ID: 16500114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease.
    Weiss HJ; Sussman II; Hoyer LW
    J Clin Invest; 1977 Aug; 60(2):390-404. PubMed ID: 17621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new variant of von Willebrand's disease (type I Padua): doublet-organized plasma von Willebrand factor oligomers in the presence of all size multimers.
    Casonato A; Pontara E; Dannhäuser D; Bertomoro A; Sartori MT; Girolami A
    Haematologia (Budap); 1994; 26(2):97-109. PubMed ID: 7890268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Standardisation of factor VIII and von Willebrand factor in plasma: calibration of the 4th International Standard (97/586).
    Hubbard AR; Rigsby P; Barrowcliffe TW
    Thromb Haemost; 2001 Apr; 85(4):634-8. PubMed ID: 11341497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. von Willebrand factor contained in a high purity FVIII concentrate (Fanhdi) binds to platelet glycoproteins and supports platelet adhesion to subendothelium under flow conditions.
    Rivera J; Escolar G; Casamiquela R; Bravo MI; Jorquera JI; Castillo R; Ordinas A; Vicente V
    Haematologica; 1999 Jan; 84(1):5-11. PubMed ID: 10091386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemostatic effect of a heat-treated factor VIII concentrate (Haemate P) in von Willebrand's disease.
    Fukui H; Nishino M; Terada S; Nishikubo T; Yoshioka A; Kinoshita S; Niinomi K; Yoshioka K
    Blut; 1988 Apr; 56(4):171-8. PubMed ID: 3128354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conformational changes in von Willebrand's factor protein: effects on the binding of factor VIII-coagulant.
    Benson RE; Jones DW; Dodds WJ
    Am J Hematol; 1986 Jun; 22(2):113-22. PubMed ID: 3085479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of factor VIII/von Willebrand factor concentrates using a modified method of von Willebrand factor multimer analysis.
    Metzner HJ; Hermentin P; Cuesta-Linker T; Langner S; Müller HG; Friedebold J
    Haemophilia; 1998; 4 Suppl 3():25-32. PubMed ID: 10028315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro studies, pharmacokinetic studies and clinical use of a high purity double virus inactivated FVIII/VWF concentrate (Immunate) in the treatment of von Willebrand disease.
    Ver Elst KM; van Vliet HD; Kappers-Klunne MC; Leebeek FW
    Thromb Haemost; 2004 Jul; 92(1):67-74. PubMed ID: 15213847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content.
    Weiss HJ; Hoyer LW; Rickles FR; Varma A; Rogers J
    J Clin Invest; 1973 Nov; 52(11):2708-16. PubMed ID: 4542944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U; Metzner HJ; Müller HG
    Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.